IVIG Privigen denied as not FDA-approved for this use by UnitedHealthcare?
Off-label use is widespread in medicine. If the literature and a recognised specialty-society guideline support the use, plans frequently approve on appeal — especially for cancer, cardiology, and rare disease.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What UnitedHealthcare typically requires
UnitedHealthcare's specific coverage criteria for ivig privigen are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The UnitedHealthcare angle on IVIG Privigen
## Why UnitedHealthcare Denied Privigen as Not FDA-Approved — and Why You Can Appeal
Privigen (immune globulin intravenous, 10%) is an FDA-approved biologic product with multiple labeled indications. A "not FDA-approved" denial from UnitedHealthcare in this context almost always means one of two things: (1) the specific indication for which Privigen was prescribed is not listed on the FDA label (an off-label use), or (2) the denial was issued in error because the reviewer or system misidentified the indication or product. Either scenario is appealable.
## Why This Denial Is Appealable
If the use is on-label, the denial is factually incorrect and should be reversed with minimal documentation. If the use is off-label, "not FDA-approved" as a stand-alone reason is insufficient grounds for denial under most plan structures. Off-label use of FDA-approved drugs is standard medical practice, and coverage is required when the use is supported by peer-reviewed evidence and recognized clinical guidelines — which is particularly well-established for IVIG in immune-mediated neurological and hematologic conditions. UHC's full-and-fair review obligation requires genuine evaluation, not a blanket label-matching rejection.
## Federal Appeal Framework
- ERISA §503 (employer plans): Entitles you to the specific clinical and coverage criteria UHC applied, and to a meaningful review of additional evidence.
- ACA §2719 / State external review: Off-label denials are reviewable by an independent external reviewer who will assess whether the use meets an evidence-based standard of accepted medical practice. Act within approximately four months of your denial notice.
- Expedited review: Available if your condition is acute or if a treatment delay creates meaningful clinical risk.
## Your Appeal Process
1. Obtain the denial letter and UHC's Privigen/IVIG coverage policy identifying the not-FDA-approved basis. 2. Pull the current FDA-approved prescribing information for Privigen and confirm whether your indication is on-label. 3. If on-label: file a Level 1 appeal attaching the prescribing information and your diagnosis documentation — this should resolve quickly. 4. If off-label: build a literature-supported appeal through internal and external review levels.
## Documentation to Gather
- FDA-approved prescribing information: The current Privigen label listing approved indications — the foundation of any on-label appeal.
- Diagnosis confirmation: Specialist notes, diagnostic workup, and relevant test results tying your condition to the indication for which Privigen was prescribed.
- For off-label uses — clinical literature: Published peer-reviewed studies and support from the relevant guideline organization (reference generically, e.g., the applicable immunology or neurology society guidance) establishing the use as consistent with accepted medical practice.
- Compendia support (off-label): Reference to recognized drug information compendia that list your indication, if applicable.
- Prescriber medical-necessity letter: Your specialist's explanation of the clinical basis and evidence support for the use, without fabricating specific statistics.
## Criteria-Mapping Strategy
Obtain UHC's published clinical policy for IVIG/Privigen and identify every criterion used to classify your use as not approved. If the policy requires FDA labeling for coverage, map your indication directly to the label language. For off-label uses, map each policy criterion to the supporting clinical evidence. Make the case that the use meets the evidentiary standard for accepted medical practice even absent an explicit FDA label expansion.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →Related appeal guides
- UnitedHealthcare denied as not FDA-approved for this use of ABA Autism
- UnitedHealthcare denied as not FDA-approved for this use of Amphetamine Stimulant
- UnitedHealthcare denied as not FDA-approved for this use of Amphetamine Stimulant Prodrug
- UnitedHealthcare denied as not FDA-approved for this use of Anti Amyloid Leqembi